The use of new genome sequencing technologies has revolutionized the field of myeloma genomics, enabling the analysis of large datasets of patient material and the identification of new genomic markers associated with disease progression and prognosis. The main new findings relating to these datasets will be presented, including the mutational landscape of myeloma, mechanisms of gene dysregulation, and the genomic abnormalities associated with poor prognosis. In addition, monitoring of patients with myeloma for therapeutic resistance and minimal residual disease will also be discussed.
Advances in Multiple Myeloma Genomics
Brian A. Walker, BSc, PhD, University of Arkansas for Medical Sciences, Little Rock, AR
Molecular Monitoring of Myeloma
Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, USA
Objectives:
- Describe findings of genomic landscape studies in myeloma and the genetic markers which relate to prognosis.
- Understand the main deregulated pathways involved in myeloma pathogenesis and association with therapy resistance.
- Discuss methods of minimal residual disease monitoring in myeloma.
Duration: 1.25 hr
Recording Date: November 8, 2019
CME/CMLE credit: 1.25 hr
Last day to purchase course and CE claim credit: December 24, 2022
